LDK378

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Ceritinib is an orally available inhibitor of the receptor tyrosine kinase activity of anaplastic lymphoma kinase (ALK) with antineoplastic activity.

Ceritinib is an orally available inhibitor of the receptor tyrosine kinase activity of anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, ceritinib binds to and inhibits wild-type ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to both the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a variety of tumor cell types.

Ceritinib

Angiogenesis

ALK

ALK; FLT3; IGF-1R; Insulin Receptor; STK22D

Cancer

——

1032900-25-6

558.14

C28H36ClN5O3S

>98%(HPLC)

Ethanol: 3 mg/mL (5.37 mM); DMSO: 20 mg/mL warmed (35.83 mM)

CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1

——

(-20℃)

With Ice Pack

≥ 2 years